NCT03728335
Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation
StatusActive, Not Recruiting
PhasePhase 2
SponsorCity of Hope Medical Center
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 17 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Trial status changed: Suspended → Active, Not Recruiting
- Eligibility criteria expanded, about 31 words
- Publications: details revised at 1 of 1 entry
- Study description expanded, about 5 words
- Stopped Recruitment suspended Sponsor's reason: Accrual goal met
- Start date: Jul 11, 2019 to Dec 23, 2019
- Site details revised at 2 of 2 sites
- Minor Site details revised at 1 of 2 sitesv16
- Notable Trial status: Suspended to Recruiting
- Site details revised at 2 of 2 sites
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Review
- Site details revised at 2 of 2 sites
Show 11 earlier versionsHide 11 earlier versions
- Notable Phase: Phase 1 to Phase 2
- Study description shortened, about 24 words
- Site details revised at 1 of 2 sites
- Study title shortened, about 8 words
- Notable Trial status: Active, Not Recruiting to Recruiting
- Enrollment target: 15 to 35
- Primary and study completion dates: Dec 15, 2024 to Jan 11, 2027
- Site details revised at 2 of 2 sites
- Notable Primary and study completion dates: Dec 15, 2023 to Dec 15, 2024v10
- Notable Primary and study completion dates: Jun 15, 2023 to Dec 15, 2023v9
- Notable Primary and study completion dates: Dec 15, 2022 to Jun 15, 2023v8
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 2 of 2 sites
- Notable Primary and study completion dates: Dec 15, 2020 to Dec 15, 2022
- Site details revised at 1 of 2 sites
- Notable Eligibility criteria expanded, about 3 words
- Interventions: Enasidenib (Drug), Enasidenib Mesylate (Drug) to Enasidenib Mesylate (Drug)
- Secondary endpoints revised (5)
- Study description expanded, about 10 words
Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 6 more changesShow less
- Eligibility criteria shortened, about 2 words
- Start date changed from estimate of Oct 15, 2019 to Jul 11, 2019
- Interventions: Enasidenib (Drug) to Enasidenib (Drug), Enasidenib Mesylate (Drug)
- Secondary endpoints revised (5)
- Study description revised
- Site details revised at 2 of 2 sites
- Notable Start date: Jun 15, 2019 to Oct 15, 2019v3
- Notable Start date: Dec 15, 2018 to Jun 15, 2019v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of adverse events (AEs)
Timeframe: Up to 30 days post treatment completion
Secondary (5)
Overall survival (OS)
Leukemia free survival (LFS)
Time to relapse
Non-relapse mortality (NRM)
Graft versus host disease (GvHD)-free relapse free survival (GRFS)
Arms and interventions
Treatment (enasidenib mesylate)Experimental
Patients receive enasidenib PO QD on days 1-28. Treatment repeats every 28 days for up to 24 cycles in the absence of disease progression or unacceptable toxicity.
Drugs: Enasidenib Mesylate
Sites
2 sites in 1 country